Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of South Carolina
With
Ochsner Health System
The study will consist of a group of subjects who have been on bosentan for at least three months and a group that has been on macitentan for at least three months. Both groups will be switched to Letairis 5mg daily after the bosentan or macitentan therapy for three months and then increased to a dose of Letairis 10mg daily at week 4 if well tolerated.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of a Connective Tissue Disease (CTD)
Age range: 18-80 years old
Previous Right Heart Catheterization (RHC) demonstrating PAH
Forced vital capacity (FVC) greater than 50%
Carbon Monoxide Diffusing Capacity (DLCO) greater than 50%
World Health Organization (WHO) functional class II or III
Able to perform a 6 minute walk test (6MWT)
Stable dose of antihypertensive medications
Non-pregnant females
Have to be currently on stable dose of bosentan for at least 3 months
Adequate acoustic images to allow for transthoracic echocardiography to be performed
You may not be if
Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)
Severe systemic hypertension greater than 170/95
Patients with a prior history of cardiovascular disease
WHO functional class IV status
Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.
FVC less than 50% of predicted
DLCO less than 50% of predicted
Clareo Health | Crossover Study From Macitentan or Bosentan Over to Ambrisentan
